Market Cap 872.79M
Revenue (ttm) 107.46M
Net Income (ttm) 105.90M
EPS (ttm) N/A
PE Ratio 17.69
Forward PE 11.03
Profit Margin 98.55%
Debt to Equity Ratio 0.00
Volume 1,619,500
Avg Vol 543,810
Day's Range N/A - N/A
Shares Out 51.55M
Stochastic %K 39%
Beta 0.17
Analysts Sell
Price Target $16.50

Company Profile

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a stra...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 808 6000
Address:
901 Gateway Boulevard, South San Francisco, United States
Mikelonggggggggg
Mikelonggggggggg Jun. 30 at 6:00 PM
1 · Reply
DeeB6999
DeeB6999 Jun. 30 at 2:08 PM
$NVAX Hi Guys, does anyone here trade these companies $ABEO and $TBPH......
1 · Reply
MikeyMcDermott
MikeyMcDermott Jun. 29 at 9:27 PM
$TBPH what is this scummy deal for no premium and a CVR. PSA: $SPRO MUST GET 100% OF CASH UPFRONT FOR TEBI RIGHTS
0 · Reply
Nickhzap
Nickhzap Jun. 29 at 4:08 PM
$TBPH $ZYME 😂😂😂🤡🤡🤡🤡
0 · Reply
mikesterz7
mikesterz7 Jun. 29 at 1:42 PM
$TBPH $ZYME Theravance Biopharma shareholders will receive a contingent value right (CVR) under which they will get 80% of the net proceeds from any future license, divestiture, or monetization of ampreloxetine over the next ten years.
0 · Reply
NotBornYesterday
NotBornYesterday Jun. 29 at 1:35 PM
$TBPH Congrats to Cowboy Boots. Two and a half decades of self-enrichment and total corporate failure. End the fucking money printing and send scumbags like Rick to the bread lines.
0 · Reply
JFais
JFais Jun. 29 at 1:04 PM
Didn't have $ZYME as an acquirer in my bingo card $TBPH (zero premium, $XBI doesn't like such deals) The next great (& unsexy) royalty aggregator (diversifying revenues & racking up tax benefits)
1 · Reply
JFais
JFais Jun. 29 at 12:58 PM
Didn't have $ZYME as an acquirer in my bingo card $TBPH
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 29 at 12:52 PM
$TBPH (-3.1% pre) Theravance Biopharma to Be Acquired by $ZYME Zymeworks for $17 Per Share Plus CVR https://ooc.bz/l/106467
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 29 at 12:44 PM
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders $TBPH $ZYME https://stocktwits.com/news/equity/markets/tbph-zyme-takeover-deal-929-million-ampreloxetine/cZ19JeQR7hM
0 · Reply
Latest News on TBPH
Zymeworks price target raised to $37 from $35 at Citi

2026-06-30T09:45:22.000Z - 4 days ago

Zymeworks price target raised to $37 from $35 at Citi

ZYME


Theravance Biopharma downgraded to Neutral from Buy at BTIG

2026-06-29T13:41:04.000Z - 5 days ago

Theravance Biopharma downgraded to Neutral from Buy at BTIG


Theravance Biopharma Proxy statement: Proxy filing

Jun 29, 2026, 8:00 AM EDT - 5 days ago

Theravance Biopharma Proxy statement: Proxy filing


Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year

2026-05-07T20:41:03.000Z - 2 months ago

Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year


Theravance Biopharma Earnings release: Q1 2026

May 7, 2026, 9:00 AM EDT - 2 months ago

Theravance Biopharma Earnings release: Q1 2026


Theravance Biopharma Quarterly report: Q1 2026

May 7, 2026, 9:00 AM EDT - 2 months ago

Theravance Biopharma Quarterly report: Q1 2026


Theravance Biopharma Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Theravance Biopharma Proxy statement: Proxy filing


Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10

2026-03-19T12:35:45.000Z - 3 months ago

Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10


Theravance Biopharma Annual report: Q4 2025

Mar 19, 2026, 8:30 AM EDT - 3 months ago

Theravance Biopharma Annual report: Q4 2025


Theravance Biopharma Earnings release: Q4 2025

Mar 19, 2026, 8:30 AM EDT - 3 months ago

Theravance Biopharma Earnings release: Q4 2025


Theravance Biopharma Slides: Corporate presentation

Mar 7, 2026, 6:00 AM EST - 4 months ago

Theravance Biopharma Slides: Corporate presentation


Theravance Biopharma downgraded to Neutral from Buy at B. Riley

2026-03-04T10:06:26.000Z - 4 months ago

Theravance Biopharma downgraded to Neutral from Buy at B. Riley


Theravance Biopharma falls 28% to $13.55 in pre-market trading

2026-03-03T13:56:44.000Z - 4 months ago

Theravance Biopharma falls 28% to $13.55 in pre-market trading


Theravance Biopharma Transcript: KOL Event

Dec 8, 2025, 10:30 AM EST - 7 months ago

Theravance Biopharma Transcript: KOL Event


Theravance Biopharma Slides: KOL Event

Dec 8, 2025, 10:30 AM EST - 7 months ago

Theravance Biopharma Slides: KOL Event


Theravance Biopharma Slides: Corporate Presentation

Nov 20, 2025, 7:00 AM EST - 8 months ago

Theravance Biopharma Slides: Corporate Presentation


Theravance Biopharma Earnings Call Transcript: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Theravance Biopharma Earnings Call Transcript: Q3 2025


Theravance Biopharma Quarterly report: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Theravance Biopharma Quarterly report: Q3 2025


Theravance Biopharma Earnings release: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Theravance Biopharma Earnings release: Q3 2025


Theravance Biopharma Slides: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Theravance Biopharma Slides: Q3 2025


Theravance Biopharma Earnings Call Transcript: Q2 2025

Aug 12, 2025, 5:00 PM EDT - 11 months ago

Theravance Biopharma Earnings Call Transcript: Q2 2025


Theravance Biopharma Quarterly report: Q2 2025

Aug 12, 2025, 5:00 PM EDT - 11 months ago

Theravance Biopharma Quarterly report: Q2 2025


Theravance Biopharma Earnings release: Q2 2025

Aug 12, 2025, 5:00 PM EDT - 11 months ago

Theravance Biopharma Earnings release: Q2 2025


Theravance Biopharma Slides: Q2 2025

Aug 12, 2025, 5:00 PM EDT - 11 months ago

Theravance Biopharma Slides: Q2 2025


Theravance Biopharma Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Theravance Biopharma Earnings Call Transcript: Q1 2025


Theravance Biopharma Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Theravance Biopharma Quarterly report: Q1 2025


Theravance Biopharma Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Theravance Biopharma Earnings release: Q1 2025


Theravance Biopharma Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Theravance Biopharma Slides: Q1 2025


Theravance Biopharma Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Theravance Biopharma Proxy statement: Proxy Filing


Theravance Biopharma Earnings Call Transcript: Q4 2024

Feb 26, 2025, 5:00 PM EST - 1 year ago

Theravance Biopharma Earnings Call Transcript: Q4 2024


Theravance Biopharma Annual report: Q4 2024

Feb 26, 2025, 5:00 PM EST - 1 year ago

Theravance Biopharma Annual report: Q4 2024


Theravance Biopharma Earnings release: Q4 2024

Feb 26, 2025, 5:00 PM EST - 1 year ago

Theravance Biopharma Earnings release: Q4 2024


Theravance Biopharma Slides: Q4 2024

Feb 26, 2025, 5:00 PM EST - 1 year ago

Theravance Biopharma Slides: Q4 2024


Theravance Biopharma Earnings Call Transcript: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Theravance Biopharma Earnings Call Transcript: Q3 2024


Theravance Biopharma Quarterly report: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Theravance Biopharma Quarterly report: Q3 2024


Theravance Biopharma Earnings release: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Theravance Biopharma Earnings release: Q3 2024


Theravance Biopharma Slides: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Theravance Biopharma Slides: Q3 2024


Theravance Biopharma Earnings Call Transcript: Q2 2024

Aug 5, 2024, 5:00 PM EDT - 2 years ago

Theravance Biopharma Earnings Call Transcript: Q2 2024


Theravance Biopharma Quarterly report: Q2 2024

Aug 5, 2024, 5:00 PM EDT - 2 years ago

Theravance Biopharma Quarterly report: Q2 2024


Theravance Biopharma Earnings release: Q2 2024

Aug 5, 2024, 5:00 PM EDT - 2 years ago

Theravance Biopharma Earnings release: Q2 2024


Theravance Biopharma Slides: Q2 2024

Aug 5, 2024, 5:00 PM EDT - 2 years ago

Theravance Biopharma Slides: Q2 2024


Theravance Biopharma Earnings Call Transcript: Q1 2024

May 13, 2024, 5:00 PM EDT - 2 years ago

Theravance Biopharma Earnings Call Transcript: Q1 2024


Theravance Biopharma Quarterly report: Q1 2024

May 13, 2024, 5:00 PM EDT - 2 years ago

Theravance Biopharma Quarterly report: Q1 2024


Theravance Biopharma Earnings release: Q1 2024

May 13, 2024, 5:00 PM EDT - 2 years ago

Theravance Biopharma Earnings release: Q1 2024


Theravance Biopharma Proxy statement: Proxy Filing

Apr 5, 2024, 8:00 AM EDT - 2 years ago

Theravance Biopharma Proxy statement: Proxy Filing


Theravance Biopharma Earnings Call Transcript: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Theravance Biopharma Earnings Call Transcript: Q4 2023


Theravance Biopharma Earnings release: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Theravance Biopharma Earnings release: Q4 2023


Theravance Biopharma Annual report: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Theravance Biopharma Annual report: Q4 2023


Mikelonggggggggg
Mikelonggggggggg Jun. 30 at 6:00 PM
1 · Reply
DeeB6999
DeeB6999 Jun. 30 at 2:08 PM
$NVAX Hi Guys, does anyone here trade these companies $ABEO and $TBPH......
1 · Reply
MikeyMcDermott
MikeyMcDermott Jun. 29 at 9:27 PM
$TBPH what is this scummy deal for no premium and a CVR. PSA: $SPRO MUST GET 100% OF CASH UPFRONT FOR TEBI RIGHTS
0 · Reply
Nickhzap
Nickhzap Jun. 29 at 4:08 PM
$TBPH $ZYME 😂😂😂🤡🤡🤡🤡
0 · Reply
mikesterz7
mikesterz7 Jun. 29 at 1:42 PM
$TBPH $ZYME Theravance Biopharma shareholders will receive a contingent value right (CVR) under which they will get 80% of the net proceeds from any future license, divestiture, or monetization of ampreloxetine over the next ten years.
0 · Reply
NotBornYesterday
NotBornYesterday Jun. 29 at 1:35 PM
$TBPH Congrats to Cowboy Boots. Two and a half decades of self-enrichment and total corporate failure. End the fucking money printing and send scumbags like Rick to the bread lines.
0 · Reply
JFais
JFais Jun. 29 at 1:04 PM
Didn't have $ZYME as an acquirer in my bingo card $TBPH (zero premium, $XBI doesn't like such deals) The next great (& unsexy) royalty aggregator (diversifying revenues & racking up tax benefits)
1 · Reply
JFais
JFais Jun. 29 at 12:58 PM
Didn't have $ZYME as an acquirer in my bingo card $TBPH
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 29 at 12:52 PM
$TBPH (-3.1% pre) Theravance Biopharma to Be Acquired by $ZYME Zymeworks for $17 Per Share Plus CVR https://ooc.bz/l/106467
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 29 at 12:44 PM
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders $TBPH $ZYME https://stocktwits.com/news/equity/markets/tbph-zyme-takeover-deal-929-million-ampreloxetine/cZ19JeQR7hM
0 · Reply
BuyingSheep
BuyingSheep Jun. 29 at 11:02 AM
$ZYME will be a big sell off today following the acquisition of $TBPH
0 · Reply
notreload_ai
notreload_ai Jun. 29 at 10:25 AM
$ZYME has entered into a definitive agreement to acquire $TBPH for $17 per share in cash, representing an equity value of approximately $929 million, plus a CVR for future ampreloxetine proceeds. The deal adds YUPELRI to Zymeworks’ portfolio. https://notreload.xyz/xy/zymeworks-to-acquire-theravance-biopharma-for-17-per-share-in-cash-plus-cvr/
0 · Reply
Itinerant
Itinerant Jun. 10 at 12:04 PM
$TBPH Price action is good. Maybe something is finally happening. I hope so.
0 · Reply
BioTechHealthX
BioTechHealthX May. 23 at 8:15 AM
$TBPH Theravance Biopharma brings together biotech volatility, specialty respiratory expertise, and restructuring pressure, creating a complicated but intriguing setup for investors tracking TBPH stock. https://biotechhealthx.com/biotech-news/heres-what-makes-theravance-biopharma-tbph-a-more-mature-biotech-stock-to-watch/
0 · Reply
BioTechHealthX
BioTechHealthX May. 23 at 7:58 AM
$CRBU $ELVN $TBPH $TRML $TRVI Small-cap biotech stocks can move fast when clinical data, FDA approvals, or acquisition rumors hit the market, and these 10 biopharma names are worth watching for investors searching for the next potential breakout healthcare stock. https://biotechhealthx.com/biotech-news/top-10-small-cap-biotech-stocks-with-billion-dollar-upside-potential/
0 · Reply
Itinerant
Itinerant May. 5 at 5:51 PM
$TBPH The company is expected to report tomorrow. The analysts expect 9 cents per share, normalized. I agree that that is a reasonable estimate. On the basis of the likely report tomorrow, the stock is fairly priced at $16 to $17. However, the data being reported is only a transitional state of finance while they execute their staff wind down. Once completed, the continuing operational state of the company is worth $22 per share. In an actual sale, the company is worth over $30 per share. I wrote the IR people and told them that they should simply set up the provision for the staff wind down costs as a liability. Then, the analysts would value the company on the resultant, terminal P&L. The analysts do report a price target of $22, which is correct, absent a take out. I doubt that the company will do this, although I believe that it would be wise. We will see soon. I am holding long for the take out that I expect.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 12 at 10:02 PM
Smaller cap (under $1B) commercial-stage biopharma M&A exit valuations as multiples of mgmt/BOD prepared revenue & gross margin forecasts. It's our experience comm'l-stage bios projected to do $1B in sales/year are acquired for 0.30 to 0.40X 10 year revenue forecasts. Generally speaking, and not all of the time but generally speaking, the larger the revenue forecast the higher the multiples. Comm'l-stage bios in this peer group are acquired for 0.15 to 0.25X 10 year revenue projections. Investors in the comm'l-stage bios below have revenue & gross margin forecasts consistent with those in this peer group (on the attachment) $ZVRA $TBPH $AQST $VALN $HRTX This is not investment advice. We're merely sharing our analysis.
4 · Reply
Itinerant
Itinerant Apr. 10 at 8:15 PM
$TBPH In my opinion, the probability of the company being sold is very high. The company has nothing in the pipeline to justify their overhead. The Board has had a "shareholder value committee" for some time and it has just been recharged. The sale is relatively easy by the nature of its assets and revenue. The company has a very nice $430 million deferred tax asset among other liquid assets. I calculate the take out price is likely at least $30, but could be more. The continuing operational value, even with the cost reductions, is about $22. The Board has no choice but to sell the company. Price action has been excellent. JMO
1 · Reply
voorbie
voorbie Apr. 8 at 7:21 PM
$TBPH TBPH is now trading at an MCAP of 850M, 400M of which is cash which implies an enterprise value of 450M. They have max possible remaining royalties of $100M on Trelegy and are making $100M/yr from Yupelri royalties in the US (licensing deal with Viatris). Yupelri was approved in China in late 2025 so I’m guessing you could double US sales and assume annual royalties on Yupelri of 200M. Both Trelegy and Yupelri are pure profit - no operating costs - so $200M licensing revenue for Yupelri should be close to $200M profit/year. Hence, the licensing revenue from Yupelri alone is much more than enterprise value of 450M. Someone will buy them. It’s just a matter of who and for how much. I ran a quick net present value on Yupelri profits (excluding remaining 100M for Trelegy) for the next 6 years at a discount rate of 15%, assuming revenue growth to $350M by year 6. Implied NPV is 800M. Add back cash and that’s 1.2B - 41% over the current MCAP, = price per share of $23.30.
1 · Reply
SuperGreenToday
SuperGreenToday Apr. 8 at 12:41 AM
$TBPH Share Price: $16.58 Contract Selected: Sep 18, 2026 $10 Calls Buy Zone: $3.82 – $4.73 Target Zone: $6.72 – $8.21 Potential Upside: 66% ROI Time to Expiration: 163 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Itinerant
Itinerant Apr. 7 at 8:03 PM
$TBPH My theory is that the analysts have run the numbers on the value of the planned operating cost reductions and the potential takeout value and have told their best clients. The institutions are now buying. Immediate target = $22
0 · Reply
Itinerant
Itinerant Apr. 7 at 7:59 PM
$TBPH Breakout: target $22.
0 · Reply